Attached files

file filename
EX-32.1 - EX-32.1 - Redpoint Bio CORPa11-14007_3ex32d1.htm
EXCEL - IDEA: XBRL DOCUMENT - Redpoint Bio CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR7.htm
EX-32.2 - EX-32.2 - Redpoint Bio CORPa11-14007_3ex32d2.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR6.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR2.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR8.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR5.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR3.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR4.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR1.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR9.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR12.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR13.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR11.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR10.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR14.htm
XML - IDEA: XBRL DOCUMENT - Redpoint Bio CORPR15.htm

Table of Contents

 

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

 

(Mark One)

 

x      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2011

 

Or

 

o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from               to             

 

Commission File Number: 000-51708

 

Redpoint Bio Corporation

(Exact name of Registrant as specified in its charter)

 

Delaware

 

22-3393959

(State or other jurisdiction of

 

(I.R.S. Employer Identification No.)

incorporation or organization)

 

 

 

7 Graphics Drive, Ewing, New Jersey 08628

(Address of principal executive offices) (Zip Code)

 

(609) 637-9700

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o

 

Accelerated filer o

 

 

 

Non-accelerated filer o

 

Smaller reporting company x

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o No x

 

The number of shares of the registrant’s common stock outstanding as of September 12, 2011 was 79,914,789.

 

 

 



Table of Contents

 

REDPOINT BIO CORPORATION

 

 

Page

 

 

ITEM 6.             EXHIBITS

1

 

 

SIGNATURES

2

 

i



Table of Contents

 

EXPLANATORY NOTE

 

Redpoint Bio Corporation (the “Company”) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011 (the “Form 10-Q”) as an exhibit only filing in order to comply with certain XBRL filing requirements in accordance with Rule 405 of Regulation S-T.  This Amendment No. 1 to Quarterly Report on Form 10-Q/A (this “Amendment”) is being filed solely to amend the Exhibit Index included in the Form 10-Q. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are filed as exhibits to this Amendment.

 

Except as described above, this Amendment does not reflect events occurring after the filing of the original Form 10-Q and no revisions are being made pursuant to this Amendment to the Company’s financial statements or any other disclosure contained in the Form 10-Q.

 

ITEM 6. EXHIBITS

 

Exhibit No.

 

 

 

 

 

10.1

 

Discounted Payoff Agreement, by and between Redpoint Bio Corporation and CIT Healthcare LLC, dated May 11, 2011 (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, dated May 11, 2011, and filed on May 12, 2011).

 

 

 

32.1

 

Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

 

 

 

32.2

 

Certification of principal accounting and financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

 

 

 

101.INS

 

XBRL Instance Document*

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document*

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document*

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document*

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document*

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document*

 


* Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

1



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

REDPOINT BIO CORPORATION

 

 

 

September 14, 2011

By:

/s/ F. Raymond Salemme

 

 

F. Raymond Salemme

 

 

President and Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

September 14, 2011

By:

/s/ Scott M. Horvitz

 

 

Scott M. Horvitz

 

 

Chief Financial Officer, Treasurer and Secretary

 

 

(Principal Financial and Accounting Officer)

 

2



Table of Contents

 

EXHIBIT INDEX

 

Exhibit No.

 

 

 

 

 

10.1

 

Discounted Payoff Agreement, by and between Redpoint Bio Corporation and CIT Healthcare LLC, dated May 11, 2011 (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, dated May 11, 2011, and filed on May 12, 2011).

 

 

 

32.1

 

Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

 

 

 

32.2

 

Certification of principal accounting and financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

 

 

 

101.INS

 

XBRL Instance Document*

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document*

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document*

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document*

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document*

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document*

 


* Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

3